• Categories:Company News
• Author:
• Origin:
• Time of issue:2021-10-27 00:00
• Views:

(Summary description)On October 27, 2021, Official announcement issued by our company: Cosychem Technology (Tianjin) Co., Ltd. (Abbreviation: Cosychem) completed A round of financing of nearly 100 million yuan, led by Tianchuang capital, followed by Bozheng capital and Xinghan capital as the exclusive financial consultant. This round of financing will be mainly used for the construction of the company's production base and the R & D of new products, While consolidating the CDMO business of small molecule innovative drugs, it will further accelerate the production and transformation of core raw material business in the field of IVD. This financing is the first external financing of our company. In the development process of the first 10 years, Cosychem has completed the growth of output value from 0 to 100 million yuan by relying on its independent growth ability, and its business has gradually expanded from early CRO service to CDMO business. In the field of small molecule CDMO with relatively fierce competition, relying on years of experience in chemical synthesis and production amplification, our company has become the core supplier of many leading pharmaceutical enterprises. In 2013, our company began to layout IVD raw materials and successfully developed several key IVD raw material products such as dNTP and fluorescent probe. Our company will also further deepen the construction of R & D platform with the support of this financing. "In the past, the company focused on technology R & D services, and most of the orders were customized products with high added value but less volume. In the future, the company will focus on large-scale production of key technical achievements, create products with market leading position, provide one-stop services from R & D to production, and establish the Cosychem brand to realize early intervention and deep binding of the innovative pharmaceutical projects We will keep the key core technologies in our own hands and make continuous efforts for the rapid and stable development of biomedicine." Mr Yanmin Song, founder of the company, said.